AGA Offers New Guidance on FMT Therapies To Prevent C. diff

Treatment with FMT is effective for preventing recurrent Clostridioides difficile infection in adults with robust ...

APRIL 18, 2024

Phase 3 Data Show Rebyota Safe, Effective in Reducing Recurrent CDI

The FDA approved the microbiota-based live biotherapeutic RBX2660 (Rebyota, Ferring) to prevent recurrent ...

DECEMBER 10, 2022

FDA Approves Rebyota, the First Live Biotherapeutic Fecal Microbiota Product in the U.S.

RBX2660 (Rebyota, Ferring) is approved by the FDA for the prevention of recurrent Clostridioides difficile ...

DECEMBER 2, 2022

Impact of Live Biotherapeutic Products on C. difficile Recurrence

It is estimated that 500,000 people in the United States test positive for Clostridioides difficile infection (CDI) ...

NOVEMBER 17, 2022

Phase 3 Data Show RBX2660 Safe, Effective in Reducing Recurrent CDI

The microbiota-based live biotherapeutic RBX2660 (Ferring) has been proven to be an effective and safe treatment ...

NOVEMBER 8, 2022

Novel Biotherapeutic Safe, Efficacious in Treating Recurrent CDI

RBX2660, a novel microbiota-based live biotherapeutic, consistently reduced rCDI among patients who are 65 years of ...

NOVEMBER 1, 2022

Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months

The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related ...

OCTOBER 10, 2022